Drug Trial Radar · NCT02511340
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Last checked: Nov 19, 2026Latest source record: Jul 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
167
Planned (sponsor's estimate)
Start
Jan 2013
Primary completion
Aug 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.
Conditions
- Chronic Myelogenous Leukemia
Interventions
Flumatinib mesylate tablet 600 mg qdDrug
Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed overall hematologic response(OHR)at 6 monthsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.